

INNOVATION IN THE DELIVERY OF INHALED NITRIC OXIDE

## GENOSYL<sup>®</sup> DELIVERY SYSTEM

SIMPLIFIED TANKLESS SOLUTION

**The First and Only iNO Delivery System Approved for Interhospital Transport Across Ground, Fixed-Wing, and Rotary-Wing Environments**

**GENOSYL<sup>®</sup> DS HAS BEEN VIGOROUSLY TESTED ACROSS ALL APPROPRIATE STANDARDS PER FDA AND FAA REQUIREMENTS**

- Proven to withstand the use environments of ground, fixed-wing, and rotary-wing transport.
- Static pull and EMI / EMC tested
- Custom transport mount created with Quick Connect Plate designed to interface with common sled connections
- Helical Mounts provide a high level of isolation from shock and vibration



USE WITH GENOSYL<sup>®</sup> ORANGE EXTERNAL TRANSPORT CASSETTES

### GENOSYL DS KEY BENEFITS

- Compact design allows for easy access during transport
- Single System allows for simple patient handoff from the acute care setting to the transport vehicle
- Cassette-based system, utilizing easily accessible 16oz pocket-sized Cassettes, eliminates the need for tanks
- Automated Cassette activation for immediate dose initiation
- Automatic Cassette transition reduces potential clinical errors



MEDICAL INFORMATION



INVENTORY MANAGEMENT



TECHNICAL SUPPORT



TRAINING AND EDUCATION



**Supporting innovation and change, our experienced, Registered RTs provide 24/7/365 support and a customized partnership to ensure success**

- 24 hours a day, 7 days a week, 365 days a year
- Distribution centers nationwide
- Over 2 million patient hours

**EVERY DAY. EVERY HOUR. EVERY MINUTE.**

For more information, contact your VERO Biotech Representative or the Partnership365™ Care Team at [vero-biotech.com](http://vero-biotech.com) or **1.877.337.4118**

## INDICATION AND IMPORTANT SAFETY INFORMATION

GENOSYL® is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.

- GENOSYL is contraindicated in the treatment of neonates dependent on right-to-left shunting of blood.
- Abrupt discontinuation of GENOSYL (nitric oxide) gas, for inhalation may lead to worsening oxygenation and increasing pulmonary artery pressure.
- Methemoglobin, NO<sub>2</sub>, and PaO<sub>2</sub> should be monitored during nitric oxide administration.
- In patients with pre-existing left ventricular dysfunction, GENOSYL may increase pulmonary capillary wedge pressure leading to pulmonary edema.
- The most common adverse reaction is hypotension.
- Nitric oxide donor compounds may have an additive effect with GENOSYL on the risk of developing methemoglobinemia.
- GENOSYL must be administered using a calibrated GENOSYL Delivery System. Only validated ventilator systems or nasal cannulas should be used in conjunction with GENOSYL.
- NO<sub>2</sub>, nitric dioxide; OR, operating room; PaO<sub>2</sub>, partial pressure of oxygen.